The Dual GIP/ GLP-1 Receptor Agonists Obesity Drugs market was valued at USD 4.75 Billion in 2024 and is expected to reach USD 17.71 Billion by 2032, growing at a CAGR of 17.85% (2025-2032). Get insights on trends, segmentation, and key players with Data Bridge Market Research Reports.